结肠癌组织标本Rho解离抑制因子2的表达及其与临床病理的关系

Expression of Rho dissociation inhibitor 2 in colon cancer tissues and its correlation with clinico-pathological features

目的探讨结肠癌Rho解离抑制因子2（RhoGDl2）基因的表达及其与临床病理的关系。方法运用组织芯片技术、免疫组织化学法检测75例结肠癌患者原发癌灶和癌旁正常结肠组织的RhoGDl2的表达及其与相应结肠癌临床病理参数之间的关系。运用Westernblot和实时定量聚合酶链反应（Real-timePCR）检测18例配对结肠腺癌原发灶组织和癌旁5cm正常结肠组织的RhoGDl2的表达。结果RhoGDl2阳性率在结肠癌原发癌灶和癌旁正常组织分别为73．33％和33．33％（P〈0．05）；RhoGDl2阳性率与临床TNM分期相关（P〈0．01），与原发灶T分期范围相关（P〈0．05），与淋巴结N分期、远处转移M无明显相关（P〉0．05）。18例结肠癌RhoGDl2Westernblot灰度值高于正常组织的4．8倍（P〈0．05）。Real-timePCR结果显示癌灶组RhoGDl2相对表达量高于癌旁对照组（P〈0．05）；RhoGDl2表达阳性率与临床TNM分期明显相关（P〈0．01），与原发灶T分期明显相关（P〈0．05）。结论RhoGDl2在结肠癌中表达上调，与临床TNM分期明显相关。

Objective To investigate the Rho dissociation inhibitor 2 （RhoGDI2） gene expression in colon cancer tissues and its correlation with clinicopathological features. Methods Tissue microarray and immunohistochemistry were used to detcet the expression of RhoGDI2 in the primary lesions and adja- cent colon tissues of 75 cases of colon cancer, and its correlation with clinicopathological features of colon cancer was analyzed. Western blotting and real-time polymerase chain reaction （Real-time PCR） were used to examine the RhoGDI2 expression in the primary lesions and adjacent colon tissues of 18 cases of co- lon adenocarcinoma. Results The positive RhoGDI2 expression rate in primary lesions and adjacent nor- mal tissues of colon cancer was 73.33% and 33.33% respectively （P 〈 0. 05）. The positive expression rate of RhoGDI2 was correlated with TNM staging significantly （ P 〈 0. 05 ） and primary tumor T lymph node N stage related to the scope （P 〈 0. 05）, but not with distant metastasis M and lymph node N stage （P〉0. 05）. The gray values of RhoGDI2 in 18 cases of colon adenocarcinoma tissues were 4. 8 times higher than normal tissues （ P 〈 0. 05 ）. Real-time PCR results revealed that the relative expression of RhoGDI2 in the primary lesions was higher than in control group （P 〈 0. 05）. Conclusion Up-regulation of RhoGDI2 expression in colon cancer is significantly correlated with TNM staging. RhoGDI2 may be one of the colon cancer prognosis factors and the potential therapeutic targets.